Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Respir Investig ; 61(2): 220-229, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36774815

ABSTRACT

BACKGROUND: Coronavirus disease (COVID-19) is overwhelming healthcare systems worldwide. This study aimed to elucidate factors that influence disease progression to pneumonia and hospitalization before and after antiviral treatment for COVID-19 in an outpatient setting. METHODS: A total of 206 high-risk patients with COVID-19 were treated with sotrovimab, remdesivir, and molnupiravir at the Toshiwakai clinic between January 4 and April 30, 2022. Of these, 49 patients visited the Toshiwakai clinic directly and were treated immediately after diagnosis (Toshiwakai-clinic study group). The remaining patients were diagnosed elsewhere, and of these, 102 patients were quarantined at home (health-center study group) and 55 at designated facilities (quarantine-facility study group) before being referred to Toshiwakai clinic. Patients were categorized into those with mild and moderate COVID-19, based on the presence of pneumonia at the initial visit to Toshiwakai clinic. RESULTS: The symptom-onset-to-diagnosis and diagnosis-to-treatment intervals were significant predictors of moderate disease. Age, dyspnea, and diagnosis-to-treatment interval at the first visit to Toshiwakai clinic were significant predictors for hospitalization even after antiviral treatment. Although the symptom-onset-to-diagnosis interval did not differ among the three study groups, the diagnosis-to-treatment and symptom-onset-to-treatment intervals were significantly longer in the health-center and quarantine-facility study groups than in the Toshiwakai-clinic study group. CONCLUSION: The symptom-onset-to-diagnosis and diagnosis-to-treatment intervals reflect diagnostic and interventional delays, respectively, which are closely related to the current COVID-19 clinical management protocol. Easy access to the clinics and immediate antiviral treatment after diagnosis may be the best methods to prevent disease progression and hospitalization in high-risk patients.


Subject(s)
COVID-19 , Humans , SARS-CoV-2 , Hospitalization , Disease Progression , Antiviral Agents , COVID-19 Testing
2.
Int J Mol Sci ; 22(20)2021 Oct 18.
Article in English | MEDLINE | ID: mdl-34681869

ABSTRACT

A woman in her 50s was a super responder to benralizumab administered for the treatment of severe bronchial asthma (BA) with eosinophilic chronic rhinosinusitis with nasal polyp (ECRS) and eosinophilic otitis media (EOM). She exhibited the gradual exacerbation of ECRS/EOM despite good control of BA approximately 1 year after benralizumab initiation. Therefore, the treatment was switched to dupilumab, and the condition of the paranasal sinuses and middle ear greatly improved with the best control of her asthma. The patient reported that her physical condition was the best of her life. However, she developed a pulmonary opacity on chest computed tomography after 6 months. Histological examination of the lung parenchyma and cell differentiation of the bronchoalveolar lavage fluid indicated atypical chronic eosinophilic pneumonia, and treatment was switched to mepolizumab. Similarly to the period of benralizumab treatment, exacerbation of ECRS/EOM reduced her quality of life approximately 10 months after the administration of mepolizumab. Dupilumab was again introduced as a replacement for mepolizumab. The clinical course and consideration of the interaction between inflammatory cells led us to speculate that interleukin-13 could play a key role in the development of ECRS/EOM with severe BA.


Subject(s)
Asthma/drug therapy , Interleukin-13 , Otitis Media/etiology , Rhinitis/etiology , Sinusitis/etiology , Anti-Asthmatic Agents/adverse effects , Anti-Asthmatic Agents/therapeutic use , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Asthma/etiology , Eosinophils/pathology , Female , Humans , Middle Aged , Nasal Polyps/drug therapy , Nasal Polyps/etiology , Otitis Media/pathology , Quality of Life , Rhinitis/drug therapy , Sinusitis/drug therapy
3.
Respir Med Case Rep ; 32: 101336, 2021.
Article in English | MEDLINE | ID: mdl-33489745

ABSTRACT

Severe bronchial asthma is a challenging disorder to treat and can impair quality of life (QOL) under conventional therapeutic modalities. We report the case of a 52-year-old woman with severe asthma associated with eosinophilic chronic rhinosinusitis (ECRS) and eosinophilic otitis media (EOM). Although the patient was treated with a full dose of inhaled corticosteroid, leukotriene receptor antagonist (LTRA), theophylline, burst use of oral corticosteroids (OCS), her asthmatic condition aggravated, disrupting her daily life. ECRS and EOM symptoms were also getting worse despite treatment with topical application of corticosteroids to the nose and ears, LTRA, and occasional use of OCS. In addition to asthmatic symptom, the patient always suffered from intractable nasal obstruction and hearing disturbance, which contributed to the heavily impaired QOL. However, the administration of benralizumab showed rapid and remarkable improvement not only in her asthmatic conditions but also in the symptoms of ECRS and EOM within a month. These results suggest that the use of benralizumab for the treatment of severe asthma with intractable ECRS and EOM should be considered when the patient's QOL is severely deteriorated.

4.
Cough ; 9(1): 4, 2013 Feb 07.
Article in English | MEDLINE | ID: mdl-23391257

ABSTRACT

BACKGROUND: Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic cough vary depending on the clinical settings and the particular interests of investigators. OBJECTIVES: The purposes of this study were first to categorize the etiology of chronic cough by its response to systematic diagnostic treatments starting from the ß2 agonist and second to sub-categorize ß2 agonist responsive cough (BRC) by the airway hyperresponsiveness. METHODS: One hundred and eighty-four never-smokers received the maximal dose of procaterol to diagnose BRC. BRC was sub-categorized into two groups with or without airway hyperresponsiveness measured by the methacholine challenge test. Sinobronchial syndrome (SBS) was diagnosed by postnasal drip symptoms and by the response to clarythromycin and carbocysteine. Atopic cough (AC) was diagnosed by the evidence of atopy and the response to cetirizine hydrochloride. Gastroesophageal reflux disease (GERD) was diagnosed by the response to rabeprazole sodium. Since we did not investigate eosinophil counts in the tissue or in the induced sputum, no diagnosis of eosinophilic bronchitis was made. RESULTS: One hundred and nine patients had BRC. Twenty-three of them had bronchial asthma (BA), 53 had cough variant asthma (CVA) and 33 had non-hyperresponsive BRC (NHBRC). Thirty-one patients had GERD, 27 had AC and 14 had SBS. Twenty-five patients had more than one diagnosis in combination, while 6 had other miscellaneous diseases. Twelve patients were undiagnosed and 11 dropped out of the study. CONCLUSIONS: The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan. TRIAL REGISTRATION: University hospital medical information network (UMIN 000007483).

5.
PLoS One ; 7(12): e50994, 2012.
Article in English | MEDLINE | ID: mdl-23227226

ABSTRACT

The height of Japanese youth raised in the northern region tends to be greater than that of youth raised in the southern region; therefore, a geographical gradient in youth body height exists. Although this gradient has existed for about 100 years, the reasons for it remain unclear. Consideration of the nutritional improvement, economic growth, and intense migration that has occurred in this period indicates that it is probably the result of environmental rather than nutritional or genetic factors. To identify possible environmental factors, ecological analysis of prefecture-level data on the body size of 8- to 17-year-old youth averaged over a 13-year period (1996 to 2008) and Japanese mesh climatic data on the climatic variables of temperature, solar radiation, and effective day length (duration of photoperiod exceeding the threshold of light intensity) was performed. The geographical distribution of the standardized height of Japanese adolescents was found to be inversely correlated to a great extent with the distribution of effective day length at a light intensity greater than 4000 lx. The results of multiple regression analysis of effective day length, temperature, and weight (as an index of food intake) indicated that a combination of effective day length and weight was statistically significant as predictors of height in early adolescence; however, only effective day length was statistically significant as a predictor of height in late adolescence. Day length may affect height by affecting the secretion of melatonin, a hormone that inhibits sexual and skeletal maturation, which in turn induces increases in height. By affecting melatonin production, regional differences in the duration of the photoperiod may lead to regional differences in height. Exposure to light intensity greater than 4000 lx appears to be the threshold at which light intensity begins to affect the melatonin secretion of humans who spend much of their time indoors.


Subject(s)
Body Height/physiology , Ecological and Environmental Phenomena , Geography , Photoperiod , Adolescent , Body Weight/physiology , Child , Climate , Female , Humans , Japan , Male , Regression Analysis
6.
Int J Environ Res Public Health ; 8(11): 4272-83, 2011 11.
Article in English | MEDLINE | ID: mdl-22163206

ABSTRACT

The influence of day length on living creatures differs with the photosensitivity of the creature; however, the possible sunshine duration (N(0)) might be an inadequate index of the photoperiod for creatures with low light sensitivity. To address this issue, the authors tried to estimate the effective day length, i.e., the duration of the photoperiod that exceeds a certain threshold of light intensity. Continual global solar radiation observation data were gathered from the baseline surface radiation network (BSRN) of 18 sites from 2004 to 2007 and were converted to illuminance data using a luminous efficiency model. The monthly average of daily photoperiods exceeding each defined intensity (1 lx, 300 lx, … 20,000 lx) were calculated [defined as Ne(() (lux) ())]. The relationships between the monthly average of global solar radiation (Rs), N(0), and Ne(() (lux) ()) were investigated. At low light intensity (<500 lx), Ne(() (lux) ()) were almost the same as N(0). At high light intensity (>10,000 lx), Ne(() (lux) ()) and Rs showed a logarithmic relationship. Using these relationships, empirical models were derived to estimate the effective day length at different light intensities. According to the validation of the model, the effective day length for any light intensity could be estimated with an accuracy of less than 11% of the mean absolute percentage error (MAPE) in the estimation of the monthly base photoperiod. Recently, a number of studies have provided support for a link between day length and some diseases. Our results will be useful in further assessing the relationships between day length and these diseases.


Subject(s)
Models, Statistical , Photoperiod , Solar Energy/statistics & numerical data , Sunlight , Circadian Rhythm , Climate , France , Japan , Regression Analysis , Seasons , Switzerland , United States , Weather
7.
Gan To Kagaku Ryoho ; 35(9): 1591-3, 2008 Sep.
Article in Japanese | MEDLINE | ID: mdl-18799918

ABSTRACT

A 64-year old man first visited our clinic approximately 10 years ago because of diabetic nephropathy that had developed into chronic renal failure. He was hospitalized to examine a left S10 tumor shadow. Based on the results of these examinations, a primary left S10 T2N0M1, ED small cell lung cancer, was diagnosed. During his outpatient visits nephropathy was found. Following admission, he began dialysis (HD). During the detailed examinations, chemotherapy with amrubicin (AMR)was performed and the blood concentration of the drug was measured. The results showed no significant variations in blood concentration before and after the dialysis. While PR was achieved in this patient, a reduction in grade 4 eosinophils was observed as an adverse reaction.


Subject(s)
Anthracyclines/adverse effects , Anthracyclines/therapeutic use , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/pathology , Kidney Failure, Chronic/complications , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Anthracyclines/blood , Carcinoma, Small Cell/complications , Carcinoma, Small Cell/diagnostic imaging , Humans , Lung Neoplasms/complications , Lung Neoplasms/diagnostic imaging , Male , Middle Aged , Neoplasm Staging , Tomography, X-Ray Computed
8.
Nihon Kokyuki Gakkai Zasshi ; 43(2): 77-83, 2005 Feb.
Article in Japanese | MEDLINE | ID: mdl-15770937

ABSTRACT

OBJECTIVE AND METHODS: To assess the clinical significance of CA19-9 in patients with interstitial pneumonia showing pathological nonspecific interstitial pneumonia (NSIP) pattern (IP/NSIP groups), we measured the levels of serum (n = 14) and bronchoalveolar lavage fluid (BALF, n = 10) CA19-9 in IP/NSIP groups. RESULT: The serum levels of CA19-9 did not correlate with the serum levels of LDH, of KL-6, or of SP-D or with the intensity of chest Ga-67 scintigraphy. There were no significant differences between the serum CA19-9 levels before therapy and those after therapy in improving patients. The levels of CA19-9 in fibrotic NSIP groups (serum:n = 7, 138.3 + /- 79.6 U/ml BALF: n = 5, 845.8 + /- 334.2 U/ml) were significantly higher than those in cellular NSIP groups (serum: n = 7, 12.8 +/-2.1 U/ml, BALF: n = 5, 40.8 +/- 16.2 U/ml). Immunohistochemical stains of CA19-9 showed the strong positivity in the bronchiolar epitheliums located in severe fibrotic lesions and the mucus within the lumens of microscopic honeycomb. The serum levels of CA19-9 were increased in both worsening patients. CONCLUSION: We speculated that the serum levels of CA19-9 may reflect the progression of lung fibrosis but not the disease activity in IP-NSIP groups.


Subject(s)
CA-19-9 Antigen/analysis , Lung Diseases, Interstitial/diagnosis , Pulmonary Fibrosis/diagnosis , Aged , Biomarkers/analysis , Biomarkers/blood , Bronchi/metabolism , Bronchoalveolar Lavage Fluid/chemistry , CA-19-9 Antigen/blood , Disease Progression , Female , Humans , Immunohistochemistry , Lung Diseases, Interstitial/pathology , Male , Middle Aged , Respiratory Mucosa/metabolism , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL